Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab treat-and-extend versus PRN for diabetic macular edema
2010-019795-74Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoints: Mean average change from baseline in best-corrected visual acuity over 12 months and Maintenance feasibility of treat-and-extend regimens. Started Jul 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2010-019795-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019795-74.